Evommune Director Arthur S. Kirsch Receives Option Award

What Happened

• Arthur S. Kirsch, a director of Evommune, was granted a derivative award on 2026-06-02 covering 15,673 shares. The reported transaction shows an acquisition price of $0.00 (i.e., no cash paid at grant). This is an award/grant (transaction code A), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-02; Form 4 filed 2026-06-03 (timely).
• Reported price: $0.00; reported as a derivative award (no immediate cash value reported).
• Shares owned after transaction: Not specified in the supplied filing data.
• Footnote: The award vests at the earlier of (i) the first anniversary of the grant date or (ii) the issuer’s next annual meeting of stockholders, subject to Kirsch’s continuous service through the vesting date.
• No 10b5-1 plan, tax‑withholding, cashless exercise, or sale was reported with this grant.

Context

• This type of grant is commonly used for director compensation and is a time‑based award rather than a market purchase or sale. It does not by itself indicate the insider bought or sold stock; vesting conditions must be met before shares are deliverable or exercisable.